ClinicalTrials.gg
Not yet recruitingNCT06989671Updated Aug 27, 2025

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

A Phase 2 interventional study of JMT101 and SYS6002 in Head and Neck Squamous Cell Carcinoma, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.

Read the detailed description

This trial consists of two parts. Part 1 (Monotherapy Group) evaluates both SYS6002 monotherapy (stratified into two cohorts by dose levels and administration frequencies) and JMT101 monotherapy. Part 2 (Combination Therapy Group) comprises Stage 1 (dose escalation phase) and Stage 2 (proof-of-concept phase). Following completion of the dose escalation phase in Part 2 and evaluation of integrated efficacy and safety analyses of SYS6002 monotherapy in Part 1 of this study as well as other clinical studies involving participants with ≥2L HNSCC, the decision on progressing to Stage 2 of Part 2 will be made through discussion between the Sponsor and investigators.

02

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
03

In context

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's planned enrollment of 430 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older, regardless of gender.
  • Able to understand and voluntarily sign a written form (ICF).
  • Confirmed recurrent or HNSCC that is not curable with local treatments. Primary tumor must be located in the oral cavity, oropharynx, hypopharynx, or larynx.
  • Able to provide well-preserved or fresh tumor tissue.
  • According to the (RECIST) v1.1, at least one confirmed by CT or MRI.
  • (ECOG) performance status score of 0-1.
  • ≥ 3 months.
  • Normal major organ function within 7 days prior to treatment.

Exclusion criteria

Exclusion Criteria:

  • Primary tumor located in the nasopharynx, nasal cavity, paranasal sinuses, salivary glands, thyroid or parathyroid glands, skin, or squamous cell carcinoma with an unknown primary site.
  • Presence of , spinal cord compression, symptomatic or progressive .
  • (Only for Stage 2 in Part 2) Prior systemic anti-tumor therapy for recurrent or HNSCC.
  • Known allergy to any component of SYS6002, JMT101, or Enlonstobart injection.
  • Participants who have previously received MMAE toxin ADC treatment (only for Part 1 and Stage 2 in Part 2).
  • Adverse events related to prior anti-tumor treatment that have not resolved to ≤ Grade 1 according to v5.0 (except for toxicities deemed low-risk by the investigator, such as Grade 2 alopecia).
  • not met for anti-tumor medications or treatments.
  • Any serious and/or uncontrolled comorbid conditions that may interfere with the participant's ability to participate in the study
  • Pregnant or breastfeeding women; women of with a positive pregnancy test within 7 days before enrollment. Breastfeeding women may participate if they stop breastfeeding, but they cannot resume breastfeeding during the treatment and after the study ends.
  • Any male or female participants of childbearing potential who refuse to use highly effective during the study and for 6 months after the last dose of study drug.
  • Unwilling or unable to comply with the study procedures and requirements, or deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    SYS6002 monotherapy (Q2W)

    Drug: SYS6002

  • Experimental
    SYS6002 monotherapy (Q3W)

    Drug: SYS6002

  • Experimental
    JMT101 monotherapy

    Drug: JMT101

  • Experimental
    SYS6002 combinational therapy (Q2W)

    Drug: JMT101 · Drug: SYS6002 · Drug: SG001

  • Experimental
    SYS6002 combinational therapy (Q3W)

    Drug: JMT101 · Drug: SYS6002 · Drug: SG001

  • Experimental
    Factorial Group

    Drug: SYS6002 · Drug: SG001

  • Experimental
    Experimental Group 1

    Drug: JMT101 · Drug: SYS6002 · Drug: SG001

  • Experimental
    Experimental Group 2

    Drug: JMT101 · Drug: SYS6002 · Drug: SG001

Interventions

  • DrugJMT101

    JMT101 Q2W or Q3W, intravenous injection

  • SYS6002 Q2W or Q3W, intravenous injection

  • DrugSG001

    SG001 Q2W or Q3W, intravenous injection

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicities (DLTs)

    Time frame: Up to 28 days

  2. Incidence of Adverse Events (AEs)

    Time frame: Up to approximately 2 years

  3. Maximum Tolerated Dose (MTD)

    Time frame: Up to approximately 2 years

  4. Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: Up to approximately 2 years

  2. Duration of Response (DOR)

    Time frame: Up to approximately 2 years

  3. Progression-free Survival (PFS)

    Time frame: Up to approximately 2 years

  4. Overall Survival (OS)

    Time frame: Up to approximately 3 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2027, 28 months later.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 28 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 25, 2025
StartEst.
Aug 30, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jul 30, 2028
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06989671
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Aug 30, 2025 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Aug 27, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Becotatug · Sutantatug Envedotin

Start the discussion